{"preliminary_commentary":{"by_channel":{"x_thread":11,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03230734\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["radium-223","docetaxel"]],"indication":"symptomatic bone-only metastatic castration-resistant prostate cancer","name":"RAPSON","nct_id":"NCT03230734","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=rapson-nct03230734. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"RAPSON","arms":[{"description":"radium-223 initially followed by docetaxel plus prednisone at the time of progression (PD)","label":"Treatment Arm A","type":"EXPERIMENTAL"},{"description":"docetaxel plus prednisone initially followed by radium-223 at the time of progression (PD)","label":"Treatment Arm B","type":"EXPERIMENTAL"}],"collaborators":["Bayer"],"completion_date":{"date":"2025-07","type":"ESTIMATED"},"conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":{"count":70,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Radium-223","otherNames":[],"type":"DRUG"},{"name":"Docetaxel","otherNames":[],"type":"DRUG"}],"last_update":"2024-09-27","lead_sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","official_title":"Randomized, Multicentre Phase II Trial of the Sequencing of Radium-223 and Docetaxel Plus Prednisone in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer (mCRPC)","overall_status":"UNKNOWN","phases":["PHASE2"],"primary_completion_date":{"date":"2025-07","type":"ESTIMATED"},"primary_outcomes":[{"measure":"health-related quality of life (HRQoL) clinical benefit","timeFrame":"up to 36 months"},{"measure":"health-related quality of life (HRQoL ) clinical benefit","timeFrame":"up to 36 months"}],"references":[],"start_date":{"date":"2017-09-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT03230734"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/rapson-nct03230734"}